HR positive + HER-2 negative
|
Male Breast Cancer
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
ribociclib Sensitive: B - Late Trials
|
ribociclib Sensitive: B - Late Trials
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
HR positive + HER-2 negative
|
Male Breast Cancer
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|